Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 September 2011: Public Health  

Phenotypic and genotypic evaluation of fluoroquinolone resistance in clinical isolates of Staphylococcus aureus in Tehran

Marzieh Aligholi ABG , Akbar Mirsalehian AD , Shahnaz Halimi BEF , Hossein Imaneini DE , Morovat Taherikalani CEG , Fereshteh Jabalameli ABG , Parisa Asadollahi EF , Babak Mohajer B , Alireza Abdollahi B , Mohammad Emaneini ACDEFG

DOI: 10.12659/MSM.881920

Med Sci Monit 2011; 17(9): PH71-74

0 Comments

Background

Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA) is of great global concern as it can cause serious infections in both hospitals and the community [1–3]. Increasing resistance to antibiotics among staphylococcal isolates limits the choices of antibiotics available to treat infections caused by these bacteria [4]. Fluoroquinolones are broad-spectrum antibiotics widely used in the treatment of bacterial infections such as gram-positive cocci; however, resistance to these antibiotics has significantly increased world-wide [5,6]. Three different mechanisms of fluoroquinolones resistance have been described in staphylococci. The first is the mutation in the grlA and grlB genes that encodes the subunits of DNA topoisomerase IV, the second is the mutation in the gyrA and gyrB genes that encode the subunits of DNA gyrase, and the third is an active efflux pump mediated by mutations in the norA gene [5–9]. In most cases, mutations occur in the highly conserved quinolone resistance-determining regions (QRDRs) of the grlA and gyrA genes [10].

Despite the high incidence of fluoroquinolones resistance among staphylococci, especially among MRSA, there is currently little information available on the incidence and the types of these resistances in many countries. This lack of information is of particular concern in the Persian Gulf region, where the prevalence of MRSA is high [9,11]. The aim of the present study was to provide information regarding the prevalence of fluoroquinolones resistance among S. aureus isolates in Tehran, Iran.

Material and Methods

BACTERIAL STRAINS:

A total of 165 S. aureus clinical isolates were cultured from patients attending 2 teaching hospitals of Tehran University of Medical Sciences between April 2009 and September 2010 (155 isolates from Imam Khomeini hospital and 10 isolates from Amir Alam hospital). They were cultured from wounds, blood, CSF, body fluid, and urine. Only 1 isolate per patient was included. Isolates were identified to species level using standard biochemical methods including Gram stain, catalase test, tube coagulase, DNase, and fermentation of mannitol [12,13].

ANTIMICROBIAL SUSCEPTIBILITY TEST:

Antibiotic-containing disks (Mast, UK) were used to determine the susceptibility of S. aureus isolates to several antibiotics according to the criteria established by the Clinical and Laboratory Standards Institute (CLSI) [14]. The antibiotics tested were ciprofloxacin, gatifloxacin, levofloxacin, norfloxacin, ofloxacin, and oxacillin. The minimum inhibitory concentrations (MIC) of ciprofloxacin, ofloxacin and oxacillin were determined using the microbroth dilution method as recommended by the CLSI guidelines. S. aureus (ATCC 29213) was used as control.

:

Chromosomal DNA was extracted from the clinical S. aureus isolate as previously described [2]. The mecA, grlA, and gyrA genes were amplified by PCR-based methods, using specific primers [10,15,16]. PCR reactions were performed in a 50 μL volume consisting of 1X PCR buffer, 3 mM MgCl2, 0.4 μg/mL of each primer, 1.5 U Taq DNA polymerase, 0.2 mM dNTP Mix and 5 μL of DNA template. The PCR conditions consisted of a pre-denaturation step at 94°C for 5 min, followed by 30 cycles of at 94°C for 40 sec, 51°C for 40 sec and 72°C for 45 sec. A final extension step was performed at 72°C for 5 min. To determine the QRDRs sequences, the PCR products of grlA and gyrA genes were sequenced with both forward and reverse strands at Macrogen (Seoul, South Korea). Sequences were compared with wild-type sequences of grlA and gyrA genes with no mutations [17].

PULSED FIELD GEL ELECTROPHORESIS (PFGE):

All fluoroquinolone-resistant S. aureus isolates were analyzed by PFGE. The entire genomic DNA was prepared as described previously [15]. After digestion with Sma I endonuclease, DNAs were separated by PFGE (APZoha, Tehran, Iran) for 24 h at 15°C, with an electric field of 6 V/cm3 in 0.5× TBE buffer. The pulse time increased from 1 to 30 sec for 11 h and 1 to 3 sec for 13 h. The gels were stained with ethidium bromide (1 μg/ml) and visualized by UV illumination. DNA from S. aureus NCTC8325 was prepared in the same way and run as molecular size standard.

Results

S. aureus strains were isolated from wounds (76), blood (42), respiratory tract (20), joint fluid (15), urine (11) and CSF (1) in this study.

Out of the 165 S. aureus isolates, 87 (52.7%) and 69 (41.8%) were resistant to methicillin and tested fluoroquinolone antibiotics, respectively. All MRSA isolates contained mecA gene and 67 (77%) isolates were resistant to fluoroquinolones. Overall, the oxacillin MIC50 and MIC90 levels among isolates of MRSA were 128 μg/ml and 512 μg/ml, respectively.

The results of mutations in the QRDRs of the gyrA and grlA genes and the MIC of ciprofloxacin and ofloxacin among fluoroquinolone-resistant S. aureus isolates examined in this study are shown in Table 1. In all the assessed isolates, a mutation in the grlA gene was observed at codon 80. Fluoroquinolone-resistant S. aureus isolates had different combinations of mutations in the gyrA gene. These mutational combinations included 45 isolates at codons 84 and 86, 23 isolates at codons 84, 86 and 106, and 1 isolate at codons 84, 86 and 90.

Among the 69 fluoroquinolone-resistant S. aureus isolates, 42 PFGE patterns were generated by digestion with SmaI, which clustered into 33 PFGE types. The majority of the isolates (52) were clustered in 16 pulsotypes (Figure 1), and 4 PFGE types displayed subtypes. Seventeen PFGE types contained a single isolate.

Discussion

The spread of antimicrobial resistance among S. aureus isolates is a worldwide problem. Since fluoroquinolones, particularly ciprofloxacin and gatifloxacin, are widely used in Iran to treat a variety of infections such as staphylococcal infections [18], fluoroquinolone resistance has posed a serious challenge to the Iranian medical community. This study aimed to characterize the phenotypic and genotypic resistance to fluoroquinolone among S. aureus isolates in Tehran, Iran.

The high prevalence rate of MRSA (52.7%) in the present study is alarming and indicates an increase in the prevalence of MRSA isolates in Tehran. The previous prevalence rate reported in Tehran teaching hospitals in 2008 was 36% [15]. This finding highlights the importance of modified empiric therapy and infection control policies among hospitals in Iran.

The results of this study show a fluoroquinolone resistance rate of 41.8% among S. aureus isolates, which was higher than the 13% to 20.7% reported by similar investigations [19, 20]. Many studies have shown that 1 or 2 point mutations in the QRDRs region of both grlA and gyrA genes are the main mechanisms of fluoroquinolone resistance, in particular ciprofloxacin resistance, among S. aureus isolates [6,16,21,22]. In agreement with many other studies, the results showed that all the fluoroquinolone-resistant isolates had a single mutation at codon 80 in the grlA gene and a mutation at codons 84 in the gyrA gene [16,17,23]. Among the 69 tested isolates, 23 had an additional mutation at codon 106 and 1 had a mutation at codon 90 in the gyrA gene. The mutation at codon 106 has also been reported in a few studies, but its effect on resistance was reported to be unknown [17,21]. According to our literature review, the point mutation at codon 90 (Tyr to Ser) in the gyrA gene has not been reported previously and further studies are needed to determine its effect on fluoroquinolone resistance. In the current study, all the fluoroquinolone-resistant isolates had a mutation at codon 86 in the gyrA gene; this point mutation is a silent mutation and has already been reported by others [8,24].

Our results are consistent with those of others who found that the same mutations in the QRDRs were detected in different PFGE types, and different combinations of mutations were also found in the isolates of the same PFGE type [10,16,25].

Conclusions

In conclusion, our findings show that fluoroquinolone-resistant S. aureus strains isolated from teaching hospitals in Tehran have multiple mutations in the QRDRs region of both grlA and gyrA genes.

References

1. Brumfitt W, Hamilton-Miller JM: Drugs Exp Clin Res, 1990; 16; 205-14, pmid: 2078988

2. Emaneini M, Taherikalani M, Eslampour MA, Phenotypic and genotypic evaluation of aminoglycoside resistance in clinical isolates of staphylococci in Tehran, Iran: Microb Drug Resist, 2009; 15; 129-32, pmid: 19432516

3. Nicholas BD, Bhargave G, Hatipoglu A: Med Sci Monit, 2010; 16(8); CR365-68, pmid: 20671612

4. Chambers HF, Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications: Clin Microbiol Rev, 1997; 10; 781-91, pmid: 9336672

5. Hooper DC, Fluoroquinolone resistance among Gram-positive cocci: Lancet Infect Dis, 2002; 2; 530-38, pmid: 12206969

6. Schmitz FJ, Higgins PG, Mayer S, Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance: Eur J Clin Microbiol Infect Dis, 2002; 21; 647-59, pmid: 12373497

7. Horii T, Suzuki Y, Takeshita A, Maekawa M: Chemotherapy, 2007; 53; 104-9, pmid: 17202817

8. Tanaka M, Wang T, Onodera Y, Mechanism of quinolone resistance in Staphylococcus aureus: J Infect Chemother, 2000; 6; 131-39, pmid: 11810552

9. Tanaka M, Onodera Y, Uchida Y, Sato K: Antimicrob Agents Chemother, 1998; 42; 3044-46, pmid: 9797253

10. Iihara H, Suzuki T, Kawamura Y: Diagn Microbiol Infect Dis, 2006; 56; 297-303, pmid: 16769192

11. Fatholahzadeh B, Emaneini M, Gilbert G: Microb Drug Resist, 2008; 14; 217-20, pmid: 18694326

12. Mahon CR, Lehman DC, Manuselis G: Text book of diagnostic microbiology, 2007, Philadelphia, PA, USA

13. Reisner SB, Woods GL, Thomson RP, Specimen collection: Manual of clinical microbiology, 1999; 64-76, Washington, DC, American Society for Microbiology

14. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement, 2011; 31; M100-S21

15. Fatholahzadeh B, Emaneini M, Aligholi M: Jpn J Infect Dis, 2009; 62; 309-11, pmid: 19628913

16. Horii T, Suzuki Y, Monji A, Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs: Diagn Microbiol Infect Dis, 2003; 46; 139-45, pmid: 12812718

17. Schmitz FJ, Jones ME, Hofmann B: Antimicrob Agents Chemother, 1998; 42; 1249-52, pmid: 9593159

18. Emaneini M, Aligholi M, Hashemi FB: J Hosp Infect, 2007; 66; 92-93, pmid: 17428579

19. Blumberg HM, Rimland D, Carroll DJ: J Infect Dis, 1991; 163; 1279-85, pmid: 2037793

20. Marangon FB, Miller D, Muallem MS: Am J Ophthalmol, 2004; 137; 453-58, pmid: 15013867

21. Coskun-Ari FF, Bosgelmez-Tinaz G: Eur J Med Res, 2008; 13; 366-70, pmid: 18952518

22. Takahata M, Yonezawa M, Kurose S: J Antimicrob Chemother, 1996; 38; 543-46, pmid: 8889728

23. Yoon EJ, Lee CY, Shim MJ: Chemotherapy, 2010; 56; 153-57, pmid: 20407243

24. Wang T, Tanaka M, Sato K: Antimicrob Agents Chemother, 1998; 42; 236-40, pmid: 9527766

25. Noguchi N, Okihara T, Namiki Y: Int J Antimicrob Agents, 2005; 25; 374-79, pmid: 15848290

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750